Article Text

Download PDFPDF
Systematic review and meta-analysis
High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events
  1. Anthony A Bavry
  1. College of Medicine, Department of Medicine, University of Florida, Gainesville, Florida, USA
  1. Correspondence to Anthony A Bavry
    College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA; bavryaa{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


In the current era, periprocedural myocardial infarction (MI) can still occur in a significant proportion of percutaneous coronary interventions (PCIs).1 Large periprocedural ischaemic events are associated with harm; however, even small increases in cardiac enzymes have been associated with increased long-term mortality.2 Attempts to enhance the safety of PCI have typically occurred through the use of potent antiplatelet agents (eg, aspirin, ADP receptor blockers (clopidogrel and prasugrel) and glycoprotein inhibitors (abciximab and eptifibatide)), as well as antithrombin agents (eg, unfractionated heparin, low-molecular weight heparin and bivalirudin). Although antiplatelet and antithrombin agents are effective at reducing ischaemic events, a cost from their use is sometimes paid in terms of major …

View Full Text


  • Competing interests Novartis Pharmaceuticals, American College of Cardiology Cardiosource